MedTrace Logo

Effectiveness Study of Single Photon Emission Computed Tomography (SPECT) Versus Positron Emission Tomography (PET) Myocardial Perfusion Imaging

NCT00976053 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2014-10-31

No results posted yet for this study

Summary

The purpose of this study is to compare pharmacologic stress myocardial perfusion PET with pharmacologic stress myocardial perfusion SPECT in a near-simultaneous, head-to-head comparison in the same patient. The investigators hypothesize that pharmacologic stress myocardial perfusion PET will prove superior to pharmacologic stress myocardial perfusion SPECT as a first-line diagnostic test for higher-risk patients with known coronary artery disease (CAD) who present with symptoms consistent with possible worsening of their CAD.

Conditions

Interventions

PROCEDURE

Myocardial perfusion imaging

Randomization assignment to one of SPECT or PET myocardial perfusion imaging

Sponsors & Collaborators

  • Blue Cross Blue Shield

    collaborator OTHER

  • Cardiovascular Imaging Technologies

    collaborator INDUSTRY

  • Saint Luke's Cardiovascular Consultants

    collaborator OTHER

  • Mid America Heart Institute

    collaborator OTHER

  • Aspire Foundation

    lead OTHER

Principal Investigators

  • Timothy M Bateman, M.D. · Aspire Foundation

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2013-09-30
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00976053 on ClinicalTrials.gov